The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019.

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

Primary Biliary Cholangitis Market. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Primary Biliary Cholangitis Market Opportunities and Strategies to 2034" report has been added to ...

Primary biliary cholangitis treatment involves medications to slow progression and relieve symptoms. Advanced cases might eventually require a liver transplant.

A progressive liver condition affects thousands of Americans, but early symptoms are often dismissed as everyday ailments.

The FDA has accepted for review the NDA for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis.

Lisa Woodcock's initial instinct when she first developed severe itching all over her body was to blame an allergic reaction ...

The trial’s primary objective was to evaluate the efficacy and safety of linerixibat compared to placebo in treating cholestatic pruritus in patients with PBC. The trial was conducted across 19 ...